

Raluca Ionescu-Ittu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/809430/publications.pdf>

Version: 2024-02-01

30
papers

343
citations

933447

10
h-index

839539

18
g-index

30
all docs

30
docs citations

30
times ranked

702
citing authors

#	ARTICLE	IF	CITATIONS
1	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	2.4	73
2	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 968-977.e2.	1.2	43
3	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	2.9	32
4	Overall survival in patients with glioblastoma before and after bevacizumab approval. <i>Current Medical Research and Opinion</i> , 2018, 34, 813-820.	1.9	31
5	In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , 2020, 8, 943-953.	4.1	26
6	Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. <i>Epilepsia Open</i> , 2019, 4, 581-592.	2.4	19
7	Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 145-156.	2.5	16
8	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 2907-2921.	2.4	12
9	Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab+carboplatin+paclitaxel and carboplatin+paclitaxel: A retrospective cohort study. <i>Lung Cancer</i> , 2014, 86, 350-357.	2.0	11
10	Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. <i>SpringerPlus</i> , 2016, 5, 395.	1.2	11
11	Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. <i>Lung Cancer</i> , 2018, 119, 112-119.	2.0	11
12	Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 480-490.	1.9	11
13	Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication. <i>BMC Infectious Diseases</i> , 2018, 18, 438.	2.9	8
14	Healthcare resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14366.	3.0	8
15	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.5	6
16	Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan. <i>Cardiology and Therapy</i> , 2021, 10, 211-228.	2.6	6
17	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.	2.6	5
18	The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data. <i>Advances in Therapy</i> , 2020, 37, 4709-4719.	2.9	5

#	ARTICLE	IF	CITATIONS
19	Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up. <i>Blood</i> , 2013, 122, 4038-4038.	1.4	2
20	Overall survival in patients with glioblastoma before and after bevacizumab approval.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2062-2062.	1.6	2
21	Work productivity loss in patients with tenosynovial giant cell tumors in the United States.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22527-e22527.	1.6	2
22	Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States. <i>Pediatric Rheumatology</i> , 2021, 19, 143.	2.1	1
23	Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11601-e11601.	1.6	1
24	Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings. <i>Rheumatology and Therapy</i> , 2022, 9, 265-283.	2.3	1
25	HSR21-063: Treatment Patterns Among Patients With EGFR Mutated Metastatic NSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, HSR21-063.	4.9	0
26	Access to biomarker testing in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20655-e20655.	1.6	0
27	Access to specialist care and treatment in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9094-9094.	1.6	0
28	Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 196-196.	1.6	0
29	Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.. <i>Journal of Clinical Oncology</i> , 2018, 36, 496-496.	1.6	0
30	Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.. <i>Journal of Clinical Oncology</i> , 2018, 36, 92-92.	1.6	0